// App-Quantinova.ai

TPS9104 : Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous nonsmall cell lung carcinoma (NSCLC): KEYNOTE-189.

Researchers

Presenter

  • Richard Delmar Hall

Principal Investigators

  • Shirish M. Gadgeel

  • Edward B. Garon

  • Emilio Bria

  • Martin Reck

  • John Vida

  • Honghong Zhou

  • Harry Raftopoulos

  • Leena Gandhi

Medical Centers

  • University of Virgina, Charlottesville, VA

  • Karmanos Cancer Institute, Detroit, MI

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • University of Verona, Verona, Italy

  • Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

  • Merck & Co., Inc., Kenilworth, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Germany

  • Italy

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Pemetrexed

  • Cisplatin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02578680

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved